191 related articles for article (PubMed ID: 12058869)
1. Effect of commercial ethanol propolis extract on the in vitro growth of Candida albicans collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis.
Martins RS; Péreira ES; Lima SM; Senna MI; Mesquita RA; Santos VR
J Oral Sci; 2002 Mar; 44(1):41-8. PubMed ID: 12058869
[TBL] [Abstract][Full Text] [Related]
2. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
3. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Anil S; Ellepola AN; Samaranayake LP
J Oral Pathol Med; 2001 Sep; 30(8):481-8. PubMed ID: 11545239
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
Samaranayake YH; Samaranayake LP; Tsang PC; Wong KH; Yeung KW
J Oral Pathol Med; 2001 Jul; 30(6):336-46. PubMed ID: 11459319
[TBL] [Abstract][Full Text] [Related]
5. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.
Patton LL; Bonito AJ; Shugars DA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):170-9. PubMed ID: 11505264
[TBL] [Abstract][Full Text] [Related]
7. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
8. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
9. Oral candidiasis treatment with Brazilian ethanol propolis extract.
Santos VR; Pimenta FJ; Aguiar MC; do Carmo MA; Naves MD; Mesquita RA
Phytother Res; 2005 Jul; 19(7):652-4. PubMed ID: 16161031
[TBL] [Abstract][Full Text] [Related]
10. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of 95 yeast strains isolated from oral mycoses in HIV-negative and HIV-positive patients.
Mareş M; Mareş M; Rusu M
Bacteriol Virusol Parazitol Epidemiol; 2008; 53(1):41-2. PubMed ID: 19241996
[TBL] [Abstract][Full Text] [Related]
12. [Factors related to oral candidiasis in HIV children and adolescents, species characterization and antifungal susceptibility].
Castillo-Martínez NA; Mouriño-Pérez RR; Cornejo-Bravo JM; Gaitán-Cepeda LA
Rev Chilena Infectol; 2018 Aug; 35(4):377-385. PubMed ID: 30534924
[TBL] [Abstract][Full Text] [Related]
13. [Oropharyngeal candidiasis resistant to fluconazole in patients infected by HIV].
Drobacheff C; Manteaux A; Millon L; Reboux G; Barale T; Laurent R
Ann Dermatol Venereol; 1996; 123(2):85-9. PubMed ID: 8761757
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis.
Barchiesi F; Arzeni D; Del Prete MS; Sinicco A; Falconi Di Francesco L; Pasticci MB; Lamura L; Nuzzo MM; Burzacchini F; Coppola S; Chiodo F; Scalise G
J Antimicrob Chemother; 1998 May; 41(5):541-8. PubMed ID: 9630407
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
Menon T; Umamaheswari K; Kumarasamy N; Solomon S; Thyagarajan SP
Acta Trop; 2001 Oct; 80(2):151-4. PubMed ID: 11600094
[TBL] [Abstract][Full Text] [Related]
16. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review.
White A; Goetz MB
Clin Infect Dis; 1994 Oct; 19(4):687-92. PubMed ID: 7803633
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Candida albicans isolates from the oral cavities of HIV-positive patients to histatin-5.
Nikawa H; Jin C; Makihira S; Hamada T; Samaranayake LP
J Prosthet Dent; 2002 Sep; 88(3):263-7. PubMed ID: 12426495
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.
Sangeorzan JA; Bradley SF; He X; Zarins LT; Ridenour GL; Tiballi RN; Kauffman CA
Am J Med; 1994 Oct; 97(4):339-46. PubMed ID: 7942935
[TBL] [Abstract][Full Text] [Related]
19. [Candida albicans morphotypes and in vitro adhesivity to cells of the human oral mucosa in HIV-positive and AIDS patients after exposure of blastospores to fluconazole. II].
Spadari E; Arosio M; Malighetti V; Bellotti MG; Artini MZ; Spadari F; Riviera L
Minerva Stomatol; 1998; 47(7-8):293-7. PubMed ID: 9793362
[TBL] [Abstract][Full Text] [Related]
20. Treatment of oropharyngeal candidiasis in HIV-positive patients.
Greenspan D
J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S51-5. PubMed ID: 7915732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
